OTX-TKI: Inside the SOL-1 Data - Takeaways - MDSpire

OTX-TKI: Inside the SOL-1 Data

At ASRS 2026, Dilsher S. Dhoot, MD, FASRS, shared additional phase 3 SOL-1 data on vision maintenance, rescue treatment, and safety with investigational OTX-TKI (Axpaxli) in neovascular AMD.

  • By

  • Dilsher S. Dhoot, MD

  • July 15, 2026

  • 3 min

Share

  • 1

    The SOL-1 trial compared OTX-TKI (Axpaxli) to aflibercept (Eylea) in treatment-naïve patients with neovascular AMD.

  • 2

    The primary endpoint of vision maintenance was met with 74% of OTX-TKI patients maintaining vision compared to 56% for aflibercept.

  • 3

    At 52 weeks, 66% of OTX-TKI patients maintained vision, while 44% of those on aflibercept did.

  • 4

    30% of OTX-TKI patients required rescue treatment by week 52, compared to the same proportion in the aflibercept group by week 28.

  • 5

    OTX-TKI was found to be safe and well tolerated, with common adverse events similar to those expected from intravitreal injections.

Original Source(s)

OTX-TKI: Inside the SOL-1 Data

  • by Dilsher S. Dhoot, MD

  • July 15, 2026

Related Content

Amniotic Dressing Shows NHS Promise

UK NHS study finds clinic-based treatment may help corneal wounds heal sooner

  • July 21, 2026

  • 3 min
The Promise of Gene Therapy

With phase 3 topline data for sura-vec expected later this year, Arshad M. Khanani, MD, FASRS, reflects on how gene therapy could transform long-term treatment for nAMD.

SGLT2 inhibitors and diabetic retinopathy progression: evidence from a retrospective cohort study and Mendelian randomization analysis